Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd at NWR Communications Virtual Small Cap Investor Conference Transcript

Mar 26, 2020 - Mar 28, 2020 / NTS GMT
Release Date Price: $0.86
Paul Rennie
Paradigm Biopharmaceuticals LTD - CEO & MD

So I'd like to welcome everyone to the presentation by Paradigm. And this is an updated presentation just to bring everyone up to speed with where we are with our clinical development programs. I'd like to thank everyone for attending. And given the short time available for the presentation, I will be flicking through some slides. And in some cases, just leaving the slides for you to read at your leisure. We will be putting the presentation up on our website after we've gone through this presentation.

Now in terms of Paradigm's mission, again, that's there for you to read. I just wanted to highlight that Paradigm's aim is to develop and commercialize an ethical, safe, and effective pharmaceutical agent, of course, the bene's PPS for the treatment of musculoskeletal disorders in humans with degenerative disease driven by injury, an alphavirus infection, aging, or genetic predisposition as in the case of MPS.

In terms of the COVID-19 update, I think the take-home message here is that Paradigm has, since its inception,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot